A new radioimmunotherapy approach has been shown to successfully eliminate cancer stem cells (CSCs) in preclinical models of ovarian cancer, outperforming the current gold standard. This research, published in the July issue of The Journal of Nuclear Medicine, lays the foundation for further development of radionuclide therapies targeting CSCs, offering renewed hope for more effective treatment options and improved outcomes for patients.
This article was originally published on MedicalXpress.com
